910 Clopper Road
Suite 201S
Gaithersburg, MD 20878
United States
240-654-1450
http://altimmune.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 25
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Vipin K. Garg | Pres, CEO & Director | 566.63k | N/A | 1958 |
Mr. William Michael Brown | CFO & Principal Accounting Officer | 443.16k | N/A | 1982 |
Dr. Matthew Scott Harris M.D., MS, FCAP, AGAF | Chief Medical Officer | 371.29k | N/A | 1953 |
Mr. Bertrand Georges Ph.D. | Chief Technology Officer | N/A | N/A | N/A |
Dr. M. Scot Roberts | Chief Scientific Officer | N/A | N/A | 1959 |
Mr. José Ochoa | Chief Bus. Officer | N/A | N/A | N/A |
Altimmune, Inc., a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.
Altimmune, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.